Alzheimer’s Drug Discovery Foundation – Neuroimaging and CSF Biomarker Program
Expire le 15 septembre 2025
The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.
Specifically, this RFP focuses on: Developing novel PET ligands for clinical trials; Supporting novel CSF biomarkers; Validating innovative MRI approaches in larger cohorts and Developing novel measures of functional activity such as EEG.